Global Glucose Injection Market Growth: Industry Size, Analysis and Forecast
Report ID : 1322618 | Published : May 2025 | Study Period : 2023-2033 | Format : PDF + Excel
The market size of the Glucose Injection Market is categorized based on Formulation Type (Dextrose Injection, Dextrose 5%, Dextrose 10%, Dextrose 25%, Dextrose 50%) and Application (Diabetes Management, Nutritional Supplement, Fluid Replacement, Emergency Care, Other Applications) and Delivery Method (Intravenous, Subcutaneous, Intramuscular, Oral, Other Delivery Methods) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).
The market size of Glucose Injection Market, valued at $1.2 billion in 2023, is projected to reach $2.5 billion by 2033, expanding at a CAGR of 7.8% between 2024 and 2033. The report comprises various segments and analyzes significant trends and factors influencing market growth.
The healthcare sector that focuses on the Glucose Injection Market has a vital role. The reason is the rising incidence of diabetes and the market's need for more efficiency in treatment modalities. Glucose injections are essential during instances of hypoglycemia as they assist with patients with dangerously low blood sugar levels to recover. Increases in health awareness and healthy individuals that demand glucose regulation in time will be an opportunity for massive market expansion. This says more about the integration of ICT in medicine and the expansion of healthcare investments.
In addition, the focus on preventive healthcare across the globe raises concern on glucose control which in return creates the need for glucose injection products. Drug manufacturers are set out on a quest to bring innovations by working on advanced and more efficacious formulations remodels and covenient delivery systems that improve efficiency. As the market continues to develop, different players have plenty of the possibilities to seek new collaborations, deal with existing regulations, and embrace changes within the growth phase of this vibrant market.
| ATTRIBUTES | DETAILS |
| STUDY PERIOD | 2023-2033 |
| BASE YEAR | 2023 |
| FORECAST PERIOD | 2024-2033 |
| HISTORICAL PERIOD | 2023-2024 |
| UNIT | VALUE (USD BILLION) |
| KEY COMPANIES PROFILED | B. Braun Melsungen AG, Fresenius Kabi AG, Hospira (a subsidiary of Pfizer Inc.), MediRite, Otsuka Pharmaceutical Co. Ltd., Sandoz International GmbH, Baxter International Inc., Grifols S.A., Eisai Co. Ltd., Terumo Corporation, Bristol-Myers Squibb Company |
| SEGMENTS COVERED |
By Formulation Type - Dextrose Injection, Dextrose 5%, Dextrose 10%, Dextrose 25%, Dextrose 50%
By Application - Diabetes Management, Nutritional Supplement, Fluid Replacement, Emergency Care, Other Applications
By Delivery Method - Intravenous, Subcutaneous, Intramuscular, Oral, Other Delivery Methods
By Geography - North America, Europe, APAC, Middle East Asia & Rest of World. |
Glucose Injection Market Dynamics
The Glucose Injection Market is undergoing significant changes due to various dynamic factors. This section delves into the key drivers, restraints, opportunities, and challenges that are shaping the market landscape.
Market Drivers
- Technological Advancements
- Increasing Consumer Demand
- Regulatory Support
- Globalization
Market Restraints
- High Operational Costs
- Regulatory Challenges
- Market Saturation
Market Opportunities
- Emerging Markets
- Product Innovation
- Strategic Partnerships
Market Challenges
- Technological Disruptions
- Supply Chain Issues
- Changing Consumer Preferences
Glucose Injection Market Segmentations
Market Breakup by Formulation Type
- Overview
- Dextrose Injection
- Dextrose 5%
- Dextrose 10%
- Dextrose 25%
- Dextrose 50%
Market Breakup by Application
- Overview
- Diabetes Management
- Nutritional Supplement
- Fluid Replacement
- Emergency Care
- Other Applications
Market Breakup by Delivery Method
- Overview
- Intravenous
- Subcutaneous
- Intramuscular
- Oral
- Other Delivery Methods
Market Breakup by Region
North America
- United States of America
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Players in the Glucose Injection Market
This report provides an in-depth analysis of both established and rising industry participants. It provides broad lists of important companies organized by the types of products they offer and other market-related factors. In addition to characterizing these companies, the report contains the year each player entered the market, which is useful for research analysis by the study's analysts.
- B. Braun Melsungen AG
- Fresenius Kabi AG
- Hospira (a subsidiary of Pfizer Inc.)
- MediRite
- Otsuka Pharmaceutical Co. Ltd.
- Sandoz International GmbH
- Baxter International Inc.
- Grifols S.A.
- Eisai Co. Ltd.
- Terumo Corporation
- Bristol-Myers Squibb Company
Customization Options
Verified Industry Insights offers one of the following report customization options to our respectable clients :
Company Profiling
● Detailed profiling of additional market players (up to three players)
● SWOT analysis of key players (up to three players)
Competitive Benchmarking
● Benchmarking of key players on the following parameters : Product portfolio, geographical reach, regional presence, and strategic alliances.
Custom Research
Verified Industry Insights offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected] or call us at +1 743 222 5439
© 2024 Verified Industry Insights. All Rights Reserved